J&J racks up a fresh set of positive pivotal data for depression drug esketamine — but questions linger on safety
J&J has taken another big step forward in its quest to bring home a blockbuster approval for its nasal spray formulation of ketamine as a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
